Learn how AbbVie could help you save on IMBRUVICA®. Call 1-866-IMBRUVICA or click to learn more >

WM

Here’s to making lasting memories

Once-daily IMBRUVICA®
(ibrutinib) is the first FDA-approved therapy for adults with WM

(Waldenström’s macroglobulinemia)

Arrow

IMBRUVICA® for WM

Talk to your doctor about whether IMBRUVICA® is right for you

Learn More About IMBRUVICA® for WM

How does IMBRUVICA® work?

Learn how IMBRUVICA® is different than chemotherapy

Learn More About
How IMBRUVICA® Works

Learn from a patient

Hear from a WM patient about their experience with IMBRUVICA®

View
Patient Video

Welcome to a different way of treating WM

Starting treatment is an important time in your journey with WM. This website will help you learn more about your condition and how IMBRUVICA® can help.

IMBRUVICA® works differently from chemotherapy. For more information on how IMBRUVICA® works, go to the How Does IMBRUVICA® Work? section.1

With IMBRUVICA®, there’s a once-daily oral treatment option available to treat adults with WM1

It is not known if IMBRUVICA® is safe and effective in children.

From the moment you’re prescribed IMBRUVICA®, IMBRUVICA® By Your Side provides resources and support for getting the help you may need during treatment.*

Coverage and Cost

Confirm your coverage and out-of-pocket costs for IMBRUVICA®.

IMBRUVICA® By Your Side
Registered Nurses

Call the By Your Side Nurse Support Line at 1-888-YourSide (1-888-968-7743) if you have questions about IMBRUVICA®.

*IMBRUVICA® By Your Side patient support program is not intended to provide medical advice, replace prescribed treatment plans, or provide treatment or case management services. Patients are advised to talk to their healthcare provider and treatment team about any medical decisions and concerns they may have. By Your Side Registered Nurses are provided by Janssen Biotech, Inc. and Pharmacyclics LLC, an AbbVie Company, and do not work under the direction of your healthcare professional (HCP) or give medical advice. They are trained to direct patients to their HCP for treatment-related advice, including further referrals.

Reference: 1IMBRUVICA® (ibrutinib) Prescribing Information.